Xilio Therapeutics
NASDAQ: XLOWaltham, US · Founded 2020 · Delaware corporation · 96 employees on LinkedIn · 11 known investors
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment. Its approach aims to achieve durable efficacy for cancer patients while avoiding the severe systemic side effects of conventional immuno-oncology agents.
Founders & leadership
Xilio Therapeutics was founded in 2020 by Rene Russo.
RR
Rene RussoinFounder · President and Chief Executive Officer
JF
Joseph FarmerExecutive
TC
Timothy ClacksonExecutive
PC
Paul ClancyNamed on SEC filing
DC
Daniel CurranNamed on SEC filing
NH
Nancy HongNamed on SEC filing
RH
Rachel HumphreyNamed on SEC filing
DL
Daniel LynchNamed on SEC filing
Board
PD
DG
MR
RW
Investors · 11
Bain Capital Life SciencesBostonvia Andrew Hack · board
Bay City CapitalSan Rafael · $5M – $10M
F-Prime CapitalCambridge · $3M – $10Mvia Robert Weisskoff · board
M VenturesLos Angeles · $10.8M
MRL Ventures FundCambridge · $25M
RA CapitalBoston
RiverVest Venture PartnersSt. Louis · $500K – $3M
Solasta VenturesBoston
SV Health InvestorsBoston · $1M – $20M
Atlas VenturereportedCambridge · $500K – $1Mvia David Grayzel · board
Rock Springs CapitalreportedBaltimore
Reported raises · per SEC filings
Form D private placements$145.2M disclosed across 2 of 3 rounds · 2021–2026
▶$95MraisedFeb 2021 · 17 investors · BiotechnologyRule 506(b)
▶$95MraisedFeb 2021 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rachel HumphreyDirector
- Andrew HackDirector
- David GrayzelDirector
- Daniel LynchDirector
- Michael RossDirector
- Joseph FarmerExecutive Officer
- Rene RussoExecutive Officer, Director
- Timothy ClacksonExecutive Officer
- Paul ClancyDirector
- Daniel CurranDirector
- David GardnerDirector
- Offering amount
- $95M
- Amount sold
- $95M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$50.2MraisedJan 2021 · 16 investors · BiotechnologyRule 506(b)
▶$50.2MraisedJan 2021 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul ClancyDirector
- Daniel CurranDirector
- Peter DudekDirector
- David GrayzelDirector
- Nancy HongDirector
- Rachel HumphreyDirector
- Daniel LynchDirector
- Michael RossDirector
- Robert WeisskoffDirector
- Joseph FarmerExecutive Officer
- Rene RussoExecutive Officer, Director
- Timothy ClacksonExecutive Officer
- Offering amount
- $50.2M
- Amount sold
- $50.2M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Exelixis39 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Elicio37 shared keywordsElicio develops cancer immunotherapies including vaccines, immunomodulators, and adjuvants built on its lymph node-targeted AMP platform to activate and amplify cancer-fighting T cells. The company focuses on treating solid tumors, particularly pancreatic ductal adenocarcinoma (PDAC).
Solu34 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Bioworld29 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Xilio Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Xilio Therapeutics do?
- Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment. Its approach aims to achieve durable efficacy for cancer patients while avoiding the severe systemic side effects of conventional immuno-oncology agents.
- Who founded Xilio Therapeutics?
- Xilio Therapeutics was founded by Rene Russo in 2020.
- Who are Xilio Therapeutics's investors?
- Xilio Therapeutics's investors include Bain Capital Life Sciences, Bay City Capital, F-Prime Capital, M Ventures, MRL Ventures Fund, RA Capital, RiverVest Venture Partners, Solasta Ventures and 3 more.
- How much funding has Xilio Therapeutics raised?
- Xilio Therapeutics has disclosed $145.2M raised across 2 of its 3 known rounds.
- Where is Xilio Therapeutics headquartered?
- Xilio Therapeutics is headquartered in Waltham, US.